Literature DB >> 10751109

Olfaction in Parkinson's disease: methods of assessment and clinical relevance.

P Liberini1, S Parola, P F Spano, L Antonini.   

Abstract

Several neurological conditions have been reported to be associated with peripheral or central deficits of olfactory system. In recent years particular emphasis has been placed on the early and severe olfactory impairment in Parkinson's disease (PD), in which limited neuropathological studies have revealed a marked dopaminergic deficit in the olfactory tubercles. Moreover, indirect evidence suggests that dysfunction of the dopaminergic pathways from mesencephalon to the piriform cortex may play a role in olfactory impairment in PD. A large number of clinical studies have reported that olfactory loss in idiopathic PD is bilateral, present in hemiparkinsonism, unrelated to the stage or clinical subtype of the disease, and independent of antiparkinsonian medication. In addition, major olfactory alterations have been reported in familial PD and dementia with Lewy bodies but not in progressive supranuclear palsy and essential tremor. These findings might stimulate further research targeted to determine the biological substrate of dissimilar olfactory performances in these movement disorders. The present review summarizes standardized procedures for the assessment of olfactory acuity (detection threshold), identification (multiple choice odor naming), discrimination (differentiation between similar/dissimilar odorants), and memory (recognition of a substance previously smelled). Specific suggestions concerning the psychometric and neuropsychological evaluation of PD patients are provided.

Entities:  

Mesh:

Year:  2000        PMID: 10751109     DOI: 10.1007/pl00007803

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Olfactory functions at the intersection between environmental exposure to manganese and Parkinsonism.

Authors:  Silvia Zoni; Giulia Bonetti; Roberto Lucchini
Journal:  J Trace Elem Med Biol       Date:  2012-06-02       Impact factor: 3.849

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Olfaction in child and adolescent anorexia nervosa.

Authors:  Martin Schecklmann; Christoph Pfannstiel; Andreas J Fallgatter; Andreas Warnke; Manfred Gerlach; Marcel Romanos
Journal:  J Neural Transm (Vienna)       Date:  2011-12-20       Impact factor: 3.575

Review 4.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

5.  Laryngeal somatosensory deficits in Parkinson's disease: implications for speech respiratory and phonatory control.

Authors:  Michael J Hammer; Steven M Barlow
Journal:  Exp Brain Res       Date:  2009-12-15       Impact factor: 1.972

6.  Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Authors:  Haiyan Lou; Susana E Montoya; Tshianda N M Alerte; Jian Wang; Jianjun Wu; Xiangmin Peng; Chang-Sook Hong; Emily E Friedrich; Samantha A Mader; Courtney J Pedersen; Brian S Marcus; Alison L McCormack; Donato A Di Monte; S Colette Daubner; Ruth G Perez
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

Review 7.  Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach.

Authors:  Katie Hoyles; Jagdish C Sharma
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

8.  Airway somatosensory deficits and dysphagia in Parkinson's disease.

Authors:  Michael J Hammer; Caitlin A Murphy; Trisha M Abrams
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

Review 9.  Dietary factors in the etiology of Parkinson's disease.

Authors:  Zeynep S Agim; Jason R Cannon
Journal:  Biomed Res Int       Date:  2015-01-20       Impact factor: 3.411

10.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.